Drug Database
Back to search

United States· US:61958-1504_74c52ec6-8358-4e63-b299-64ec1ff7f434

Sovaldi

A sofosbuvir product containing sofosbuvir, registered in United States by Gilead Sciences, Inc.. The same ATC class is registered in 13 of our 19 countries.

ATC J05AP08US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedSovaldiATCJ05AP08REGISTER NO.US:61958-1504_74c52ec…PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about sofosbuvirAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Sofosbuvir is registered in 13 of 19 countries.

Countries holding a registration under ATC J05AP08 (sofosbuvir), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 8 of them publish a price we can compare per daily dose
Search sofosbuvir products by name

Sofosbuvir · ATC J05AP08

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of sofosbuvir costs, country by country.

Normalised to the WHO defined daily dose (0.4 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Sofosbuvir · price per daily dose (0.4 g)

USD · FX 28 Sept 2026

  • FR France$0.30
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
SOFOSBUVIR
Manufacturer
Gilead Sciences, Inc.
Country
United States (US)
ATC code
J05AP08
ATC class
Sofosbuvir
Defined daily dose
0.4 g, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 2

  • ndc11
    61958-1504-1
  • ndc11
    6195815041
    60 PELLET in 1 PACKET (61958-1504-1)

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

10 interactions on record for sofosbuvir.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check sofosbuvir against other medicinesHow interaction checks work

Sofosbuvir · interactions on record

10 records

  • 4 severe
  • 5 moderate
  • 1 minor

Most severe, free to view

  • LorlatinibL01ED05severe
  • LorlatinibL01XE44severe
  • EnzalutamideL02BB04severe
  • ApalutamideL02BB05severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Sofosbuvir in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All sofosbuvir products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Sovaldi
  • Liechtenstein · Sovaldi
  • Norway · Sovaldi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/cde3a808-f58c-4226-809f-ca5b86f58d23
GET /v1/drugs/cde3a808-f58c-4226-809f-ca5b86f58d23?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "150",
  "substance": "SOFOSBUVIR",
  "productndc": "61958-1504",
  "dosage_form": "PELLET",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "NDA212480",
  "marketing_category": "NDA"
}
API referenceMCP serverPlans

See everything about sofosbuvir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console